English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Saturday, August 2, 2025
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Friday, August 1, 2025
雲頂新耀宣佈增加對I-Mab的戰略投資 開發自研新一代腫瘤免疫療法的全球價值
云顶新耀宣布增加对I-Mab的战略投资 开发自研新一代肿瘤免疫疗法的全球价值
Friday, July 25, 2025
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
雲頂新耀宣布配售股份 擬集資約15.725億港元
云顶新耀宣布配售股份 拟集资约15.725亿港元
Tuesday, July 15, 2025
雲頂新耀股價創階段新高 通用型現貨腫瘤治療性疫苗EVM14「中美雙報」再釋mRNA平台潛力
云顶新耀股价创阶段新高 通用型现货肿瘤治疗性疫苗EVM14"中美双报"再释mRNA平台潜力
Friday, July 4, 2025
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
雲頂新耀發佈AI+mRNA平台新突破 重塑中國mRNA國際競爭格局

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575